Intellia Therapeutics Inc sell The Goldman Sachs Group, Inc.
Start price
28.02.25
/
50%
€9.21
Target price
28.02.26
€8.65
Performance (%)
19.35%
End price
01.03.26
€10.99
Summary
This prediction ended on 01.03.26 with a price of €10.99. The SELL prediction by The_Goldman_Sachs_Gr finished with a performance of 19.35%. The_Goldman_Sachs_Gr has a follow-up prediction for Intellia Therapeutics Inc where he still thinks Intellia Therapeutics Inc is a Sell. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | -0.387% | -0.387% | 9.621% |
| iShares Core DAX® | 0.437% | 5.897% | 8.047% |
| iShares Nasdaq 100 | 1.057% | 0.920% | 28.466% |
| iShares Nikkei 225® | 1.769% | 1.228% | 47.574% |
| iShares S&P 500 | 0.368% | 1.920% | 23.200% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "sell" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $9.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Current prediction by The_Goldman_Sachs_Gr for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€11.14
28.04.26
28.04.26
-
28.04.27
28.04.27
-6.64%
16:49
16:49
